Nanotechnology approaches to addressing HER2-positive breast cancer

White, Bryan E.; White, Molly K; Adhvaryu, Het; Makhoul, Issam; Nima, Zeid A.; Biris, Alexandru S.; Ali, Nawab

doi:10.1186/s12645-020-00068-2

Cited by 22 publications

(19 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, research has shown aspects of cellular uptake in breast cancer cell lines [ 15 ], but a study that simultaneously compares the similarities and differences in HER2-positive (SKBR3) and HER2-negative (MCF7) cytotoxicity, cellular uptake, distribution, and endocytosis mechanisms of bare gold nanorods is not available in the literature to compare with our results.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cellular Uptake of Gold Nanorods in Breast Cancer Cell Lines

White

Alsudani

et al. 2022

Nanomaterials

Self Cite

View full text Add to dashboard Cite

Nanosized materials have been proposed for a wide range of biomedical applications, given their unique characteristics. However, how these nanomaterials interact with cells and tissues, as well as how they bio-distribute in organisms, is still under investigation. Differences such as the nanoparticle size, shape, and surface chemistry affect the basic mechanisms of cellular uptake and responses, which, in turn, affects the nanoparticles’ applicability for biomedical applications. Thus, it is vital to determine how a specific nanoparticle interacts with cells of interest before extensive in vivo applications are performed. Here, we delineate the uptake mechanism and localization of gold nanorods in SKBR-3 and MCF-7 breast cancer cell lines. Our results show both differences and similarities in the nanorod–cell interactions of the two cell lines. We accurately quantified the cellular uptake of gold nanorods in SKBR-3 and MCF-7 using inductively coupled plasma mass spectrometry (ICP-MS). We found that both cell types use macropinocytosis to internalize bare nanorods that aggregate and associate with the cell membrane. In addition, we were able to qualitatively track and show intracellular nanoparticle localization using transmission electron microscopy. The results of this study will be invaluable for the successful development of novel and “smart” nanodrugs based on gold nano-structural delivery vehicles, which heavily depend on their complex interactions with single cells.

show abstract

Section: Discussionmentioning

confidence: 99%

“…ICP-MS was used to quantify cellular uptake and delineate the endocytosis mechanism via known endocytosis inhibitors. This approach has been utilized in previous cellular uptake studies [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

Cellular Uptake of Gold Nanorods in Breast Cancer Cell Lines

White

Alsudani

et al. 2022

Nanomaterials

Self Cite

View full text Add to dashboard Cite

show abstract

“…For instance, particles that are smaller in size have a higher likelihood of accumulation during incubation and storage in vitro, and characteristically have a longer half-life in circulation in vivo [169]. Several investigations have confirmed that NPs display more benefits over micrometer-sized fragments in the range of 0.1-100 µm for DDSs [170]. The biodegradation of polymer NPs can be potentially affected by their size due to rapid degradation products.…”

Section: Geometric Morphometrymentioning

confidence: 99%

Targeting Engineered Nanoparticles for Breast Cancer Therapy

et al. 2021

View full text Add to dashboard Cite

Breast cancer (BC) is the second most common cancer in women globally after lung cancer. Presently, the most important approach for BC treatment consists of surgery, followed by radiotherapy and chemotherapy. The latter therapeutic methods are often unsuccessful in the treatment of BC because of their various side effects and the damage incurred to healthy tissues and organs. Currently, numerous nanoparticles (NPs) have been identified and synthesized to selectively target BC cells without causing any impairments to the adjacent normal tissues or organs. Based on an exploratory study, this comprehensive review aims to provide information on engineered NPs and their payloads as promising tools in the treatment of BC. Therapeutic drugs or natural bioactive compounds generally incorporate engineered NPs of ideal sizes and shapes to enhance their solubility, circulatory half-life, and biodistribution, while reducing their side effects and immunogenicity. Furthermore, ligands such as peptides, antibodies, and nucleic acids on the surface of NPs precisely target BC cells. Studies on the synthesis of engineered NPs and their impact on BC were obtained from PubMed, Science Direct, and Google Scholar. This review provides insights on the importance of engineered NPs and their methodology for validation as a next-generation platform with preventive and therapeutic effects against BC.

show abstract

“…Cancer-related antigen–antibody interactions are frequently used in diagnosis, treatment, and determination of prognosis of cancers in clinical trials. It has been well appointed that HER2, a monoclonal antibody that binds to the extracellular domain (ECD) of the HER2/neu receptor, exhibits considerable expression in breast cancers (BC), serving as a potential biomarker and a detecting agent in therapeutic and prognostic case studies. − Human BC that has an overexpressed level of HER2 protein is mentioned as HER2-positive BC. HER2-positive BC commonly develops and spreads more rapidly than other BCs, and its metastatic forms are incurable, and new treatment methods are desired.…”

Section: Introductionmentioning

confidence: 99%

“…Thus, demand has increased for improvements in cancer biomarker screening and detection. The American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) published the guidelines on HER2 clarification to offer defined instructions for precise determination of HER2 levels in BC. ,, Up to now, various analysis platforms have been documented for the rapid detection of BC biomarkers such as immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and chromogenic in situ hybridization (CISH) like silver in situ hybridization (SISH), which are regarded as standard methods in clinical study and some other biochemical-based analysis including enzyme-linked immunosorbent assay (ELISA), optofluidic ring resonator (OFRR), ring resonator sensor and surface acoustic wave (SAW), electrochemical (EC), ,, surface-enhanced Raman scattering (SERS), fluorescence, ,− and colorimetric analysis . However, some of these methods are based on multipart manufacturing procedures, limiting their usage due to expensive equipment and high methodological expertise. ,, Regardless of the mentioned analysis methods, it should be noted that early and adjusted anticancer therapies with greater effectiveness of BC are just as crucial as its early recognition.…”

Section: Introductionmentioning

confidence: 99%

Design of a Ratiometric Plasmonic Biosensor for Herceptin Detection in HER2-Positive Breast Cancer

Shahbazi

Zare‐Dorabei

Naghib

2022

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Breast cancer is the most common cause of cancer death in women; therefore, its early detection and treatment are crucial. To achieve this goal, we designed an optical sensor based on direct interaction of trastuzumab [Herceptin (HER)], a monoclonal antibody used to treat HER2-positive breast cancer, with plasmonic nanoparticles. Surface-modified gold nanoparticles (AuNPs) have gained considerable attention in biosensing techniques over the last years, which actuated these nanoparticles to the heart of various biosensing notions. We have exploited the localized surface plasmon resonance (LSPR) of gold nanoparticles to determine HER in human serum. AuNPs were decorated with negatively charged citrate ions, yielding enhanced direct-surface interaction with HER antibodies. The AuNPs are mixed with silver nanoparticles (AgNPs) in an optimized ratio to increase selectivity and sensitivity further. AuNPs detect the HER antibodies using LSPR, whereas AgNPs help monitor interferences’ effect on the sensing media. The three effective factors in HER sensing, including the nanoparticle ratio, temperature, and pH were optimized via response surface methodology (RSM) based on the central composite design (CCD). The sensor’s response toward HER was achieved in the linear range of 0.5 × 10–7 to 40 × 10–7 M with the detection limit of 3.7 × 10–9 M and relative standard deviation (RSD) less than 5%. The selectivity of the LSPR sensor was assessed by monitoring its response toward HER in the presence of other biological molecules with similar physicochemical properties. Rapid response time (less than 1 min), selectivity, and the simplicity of the developed LSPR-based sensor are the key advantages of the developed sensor.

show abstract

Nanotechnology approaches to addressing HER2-positive breast cancer

Cited by 22 publications

References 34 publications

Cellular Uptake of Gold Nanorods in Breast Cancer Cell Lines

Cellular Uptake of Gold Nanorods in Breast Cancer Cell Lines

Targeting Engineered Nanoparticles for Breast Cancer Therapy

Design of a Ratiometric Plasmonic Biosensor for Herceptin Detection in HER2-Positive Breast Cancer

Contact Info

Product

Resources

About